Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…

ByNick SundichOctober 8, 2025

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat. The company made a surprising 15% plunge on the day of the announcement, and the share price has been nuanced since. However, it is still a >$500m company more than when it first listed. Let's take…

ByNick SundichOctober 1, 2025

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly. Launching 3 tests in a a year is…

ByNick SundichSeptember 26, 2025

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a unique company but when you dig deeper...it is. It is using an 'FAK inhibitor' to fight pancreatic cancer (and potentially other indications down the track). What are the Best ASX Stocks to invest in right now?…

ByNick SundichSeptember 23, 2025

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There's another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed to list on Tuesday October 7, raising $6m at 20c per share, and to have the code NXN. This company has a rapid sensing technology that it will first commercialise to detect Group B Streptococcus…

ByNick SundichSeptember 19, 2025

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

It's taken a while to get here, but the US medical device company Imagion Biosystems (ASX: IBX), which listed on the ASX way back in June 2017, is now getting to a really interesting stage of its clinical development, and has just raised $3.5m at 1.5 cents per share to fund this stage. Imagion Biosystems was…

ByNick SundichSeptember 11, 2025

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria's Post-Traumatic Stress Disorder care programme, with no out-of-pocket costs, investors who know the Life Sciences sector needed to sit up and take notice. Here was Australia's largest health insurer, with over 4.2 million customers, saying that it…

ByStuart RobertsSeptember 10, 2025

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

4 years after listing and over 7 years after its founding, Artrya (ASX:AYA) achieved the aspiration of most ASX medtechs, in obtaining FDA approval. Its Salix suite of products aims to improve the detection and treatment of Coronary Artery Disease (CAD), which is a major cause of heart attacks. Entering the US was always this company's…

ByNick SundichSeptember 10, 2025

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Think of 'America First' ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn't come to mind, but its acquisition of Galidesivir should put it firmly in the list. You cannot question the data that the company is in possession of, but some investors may think a company with plans to undertake an 'animal study' is years…

ByNick SundichAugust 27, 2025

4DMedical 100% Surge: Beginning of a Breakout or the Peak?

4DMedical Doubles in a Month: Momentum or Peak? A 100 percent share price surge in just one month will always turn heads, but the real question is whether the story has just begun or is already peaking. That’s the situation facing investors watching 4DMedical (ASX:4DX), a small-cap respiratory imaging company now riding the momentum of…

ByCharlie YouldenAugust 12, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

4DMedical 100% Surge: Beginning of a Breakout or the Peak?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here